Literature DB >> 17963827

Re: Dr. Markman's editorial "Why overall survival should not be the sole valid primary endpoint of phase 3 ovarian cancer chemotherapy trials" Gynecol. Oncol. 106(2); 279-81: 2007.

Bruce Patsner.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17963827     DOI: 10.1016/j.ygyno.2007.09.021

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


× No keyword cloud information.
  1 in total

Review 1.  CYP2D6 genotype and tamoxifen response for breast cancer: a systematic review and meta-analysis.

Authors:  Danny W K Lum; Pablo Perel; Aroon D Hingorani; Michael V Holmes
Journal:  PLoS One       Date:  2013-10-02       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.